News
Katya Kruglova to join Sonova’s Management Board as GVP Human Resources & Communications
Katya Kruglova to join Sonova’s Management Board as GVP Human Resources & Communications
Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars
Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars
Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft
Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft
EQS-Adhoc: BB Biotech AG publishes its 2022 annual report
EQS-Adhoc: BB Biotech AG publishes its 2022 annual report
Kuros Biosciences Announces Changes to Executive Management Team
Kuros Biosciences Announces Changes to Executive Management Team
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa
Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon
Relief Therapeutics Provides an Update on its Financing Strategy
Relief Therapeutics Provides an Update on its Financing Strategy
EQS-Adhoc: BB Biotech AG closes the 2022 fiscal year with a loss
EQS-Adhoc: BB Biotech AG closes the 2022 fiscal year with a loss
EQS-News: BB BIOTECH AG: Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85
EQS-News: BB BIOTECH AG: Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85
COLTENE announces key figures for the 2022 financial year
COLTENE announces key figures for the 2022 financial year
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
Evolva delivers strong results with 57% revenue growth and increasing margins
Evolva delivers strong results with 57% revenue growth and increasing margins
Sonova launches Conversation Clear Plus earbuds, expanding into the new category of early entry hearing solutions
Sonova launches Conversation Clear Plus earbuds, expanding into the new category of early entry hearing solutions
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG ("Vifor") announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining
Relief Therapeutics to Participate in January Investor Meetings
Relief Therapeutics to Participate in January Investor Meetings
Relief Therapeutics Announces Issuance of Shares from Authorized Capital
Relief Therapeutics Announces Issuance of Shares from Authorized Capital
EQS-News: BB BIOTECH AG: Molecular strike force for the immune system
EQS-News: BB BIOTECH AG: Molecular strike force for the immune system
Relief Therapeutics Announces Executive Leadership Team Changes
Relief Therapeutics Announces Executive Leadership Team Changes